{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:50:53Z","timestamp":1760953853018},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s11899-009-0041-2","type":"journal-article","created":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T08:03:25Z","timestamp":1263197005000},"page":"35-44","source":"Crossref","is-referenced-by-count":16,"title":["Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?"],"prefix":"10.1007","volume":"5","author":[{"given":"Abraham M.","family":"Varghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy C.","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,12]]},"reference":[{"issue":"1","key":"41_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","volume":"80","author":"LE Robertson","year":"1992","unstructured":"Robertson LE, Huh YO, Butler JJ, et al.: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80(1):29\u201336.","journal-title":"Blood"},{"issue":"6","key":"41_CR2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.V88.6.2228.bloodjournal8862228","volume":"88","author":"D Provan","year":"1996","unstructured":"Provan D, Bartlett-Pandite L, Zwicky C, et al.: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996, 88(6):2228\u20132235.","journal-title":"Blood"},{"issue":"1","key":"41_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"AC Rawstron","year":"2001","unstructured":"Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98(1):29\u201335.","journal-title":"Blood"},{"issue":"5","key":"41_CR4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"\u2022\u2022 Rawstron AC, Villamor N, Ritgen M, et al.: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21(5):956\u2013964 This is an attempt to standardize the flow cytometric methods for routine clinical application. Flow cytometric analysis of MRD is more practical than a PCR approach.","journal-title":"Leukemia"},{"issue":"5\u20136","key":"41_CR5","first-page":"433","volume":"30","author":"MM Hansen","year":"1988","unstructured":"Hansen MM, Andersen E, Christensen BE, et al.: CHOP versus prednisolone\u2009+\u2009chlorambucil in chronic lymphocytic leukemia (CLL): preliminary results of a randomized multicenter study. Nouv Rev Fr Hematol 1988, 30(5\u20136):433\u2013436.","journal-title":"Nouv Rev Fr Hematol"},{"key":"41_CR6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"\u2022 Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRFCLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230\u2013239 This study shows a definite advantage of fludarabine-based treatment over chlorambucil, leading to its acceptance as the standard first-line treatment.","journal-title":"Lancet"},{"issue":"1","key":"41_CR7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-07-1371","volume":"14","author":"F Bosch","year":"2008","unstructured":"\u2022 Bosch F, Ferrer A, Villamor N, et al.: Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14(1):155\u2013161 Combination chemotherapy alone can attain reasonable MRD status.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"41_CR8","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/cncr.21535","volume":"104","author":"G Poeta Del","year":"2005","unstructured":"Del Poeta G, Del Principe MI, Consalvo MA, et al.: The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70\u2013negative chronic lymphocytic leukemia. Cancer 2005, 104(12):2743\u20132752.","journal-title":"Cancer"},{"issue":"18","key":"41_CR9","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18):4079\u20134088.","journal-title":"J Clin Oncol"},{"issue":"4","key":"41_CR10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"\u2022 Tam CS, O\u2019Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4):975\u2013980 This 6-year follow-up study shows the survival advantage of MRD-negative status following immunochemotherapy.","journal-title":"Blood"},{"issue":"4","key":"41_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","volume":"27","author":"N Lamanna","year":"2009","unstructured":"Lamanna N, Jurcic JG, Noy A, et al.: Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27(4):491\u2013497.","journal-title":"J Clin Oncol"},{"key":"41_CR12","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Boettcher S, Fischer K, Stilgenbauer S, et al.: Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab\u2014a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 326 This is the first large, randomized, phase 3 trial to demonstrate that if patients can be converted from MRD positivity to negativity, then their outcome is improved.","DOI":"10.1182\/blood.V112.11.326.326"},{"issue":"3","key":"41_CR13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100(3):768\u2013773.","journal-title":"Blood"},{"issue":"35","key":"41_CR14","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"\u2022 Hillmen P, Skotnicki AB, Robak T, et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25(35):5616\u20135623 This study shows the advantage of treating CLL initially with alemtuzumab in attaining an MRD-negative status and thereby gaining survival advantage.","journal-title":"J Clin Oncol"},{"issue":"8","key":"41_CR15","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","volume":"113","author":"CS Zent","year":"2008","unstructured":"Zent CS, Call TG, Shanafelt TD, et al.: Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008, 113(8):2110\u20132118.","journal-title":"Cancer"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","volume":"119","author":"F Bosch","year":"2002","unstructured":"Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002, 119:976\u2013984.","journal-title":"Br J Haematol"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070\u20134078.","journal-title":"J Clin Oncol"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2002-10-3270","volume":"103","author":"AC Rawstron","year":"2004","unstructured":"Rawstron AC, Kennedy B, Moreton P, et al.: Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004, 103:2027\u20132031.","journal-title":"Blood"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","volume":"99","author":"B Kennedy","year":"2002","unstructured":"Kennedy B, Rawstron A, Carter C, et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002, 99:2245\u20132247.","journal-title":"Blood"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","volume":"23","author":"T Elter","year":"2005","unstructured":"Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024\u20137031.","journal-title":"J Clin Oncol"},{"key":"41_CR21","doi-asserted-by":"crossref","unstructured":"Sayala H, Moreton P, Richard JA, et al.: Final report of the UKCLL02 Trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials sub-group) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 34.","DOI":"10.1182\/blood.V108.11.34.34"},{"key":"41_CR22","doi-asserted-by":"crossref","unstructured":"Flowers C, Rosenthal H, Brown J, et al.: Analysis of minimal residual disease (MRD) from the phase 2 multicenter study of subcutaneous (SC) alemtuzumab combined with fludarabine for treatment of relapsed\/refractory B-cell chronic lymphocytic leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3111.","DOI":"10.1182\/blood.V110.11.3111.3111"},{"issue":"3","key":"41_CR23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2141.1997.1062924.x","volume":"97","author":"MJ Dyer","year":"1997","unstructured":"Dyer MJ, Kelsey SM, Mackay HJ, et al.: In vivo \u2018purging\u2019 of residual disease in CLL with Campath-1H. Br J Haematol 1997, 97(3):669\u2013672.","journal-title":"Br J Haematol"},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","volume":"98","author":"SM O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SM, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657\u20132663.","journal-title":"Cancer"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","volume":"18","author":"CM Wendtner","year":"2004","unstructured":"Wendtner CM, Ritgen M, Schweighofer CD, et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18:1093\u20131101.","journal-title":"Leukemia"},{"key":"41_CR26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","volume":"144","author":"CD Schweighofer","year":"2009","unstructured":"Schweighofer CD, Ritgen M, Eichhorst BF, et al.: Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission\u2014long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009, 144:95\u201398.","journal-title":"Br J Haematol"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971\u20132979.","journal-title":"J Clin Oncol"},{"key":"41_CR28","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sayala HA, Moreton P, Kennedy B, et al.: Eradication of minimal residual disease with alemtuzumab in chronic lymphocytic leukemia is associated with prolonged survival and is an appropriate therapeutic endpoint for relapsed CLL [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 3114 This is the follow-up of the initial study showing the survival advantage of treating relapsed\/refractory CLL with alemtuzumab.","DOI":"10.1182\/blood.V110.11.3114.3114"},{"key":"41_CR29","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","volume":"24","author":"M Montillo","year":"2006","unstructured":"Montillo M, Tedeschi A, Miqueleiz S, et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006, 24:2337\u20132342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"41_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","volume":"112","author":"G Poeta Del","year":"2008","unstructured":"\u2022 Del Poeta G, Del Principe MI, Buccisano F, et al.: Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008, 112(1):119\u2013128 This article analyzed the concept of maintenance therapy, which is found to be advantageous in some other B-cell malignancies, in CLL.","journal-title":"Cancer"},{"key":"41_CR31","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Colomer D, et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563\u20134569.","journal-title":"Blood"},{"issue":"5","key":"41_CR32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3324\/haematol.2008.000273","volume":"94","author":"L Farina","year":"2009","unstructured":"Farina L, Carniti C, Dodero A, et al.: Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94(5):654\u2013662.","journal-title":"Haematologica"},{"key":"41_CR33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.leu.2402036","volume":"15","author":"J Esteve","year":"2001","unstructured":"Esteve J, Villamor N, Colomer D, et al.: Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001, 15:445\u2013451.","journal-title":"Leukemia"},{"key":"41_CR34","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2006-04-007898","volume":"108","author":"T Zenz","year":"2006","unstructured":"Zenz T, Ritgen M, Dreger P, et al.: Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 108:2127\u20132130.","journal-title":"Blood"},{"issue":"8","key":"41_CR35","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","volume":"104","author":"M Ritgen","year":"2004","unstructured":"Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104(8):2600\u20132602.","journal-title":"Blood"},{"issue":"1","key":"41_CR36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","volume":"105","author":"DW Milligan","year":"2005","unstructured":"Milligan DW, Fernandes S, Dasgupta R, et al.: Results of the MRS pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005, 105(1):397\u2013404.","journal-title":"Blood"},{"key":"41_CR37","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","volume":"11","author":"D Caballero","year":"2005","unstructured":"Caballero D, Garcia-Marco JA, Martino R, et al.: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11:7757\u20137763.","journal-title":"Clin Cancer Res"},{"key":"41_CR38","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","volume":"23","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Sandmaier BM, et al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819\u20133829.","journal-title":"J Clin Oncol"},{"key":"41_CR39","doi-asserted-by":"crossref","first-page":"212a","DOI":"10.1182\/blood.V106.11.715.715","volume":"106","author":"S Stilgenbauer","year":"2005","unstructured":"Stilgenbauer S, Krober A, Busch R, et al.: 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG [abstract]. Blood 2005, 106:212a.","journal-title":"Blood"},{"key":"41_CR40","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567\u20131574.","journal-title":"J Clin Oncol"},{"key":"41_CR41","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554\u20133561.","journal-title":"Blood"},{"key":"41_CR42","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","volume":"94","author":"JG Perkins","year":"2002","unstructured":"Perkins JG, Flynn JM, Howard RS, et al.: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002, 94:2033\u20132039.","journal-title":"Cancer"},{"key":"41_CR43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","volume":"4","author":"M Keating","year":"2004","unstructured":"Keating M, Coutre S, Rai K, et al.: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004, 4:220\u2013227.","journal-title":"Clin Lymphoma"},{"key":"41_CR44","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","volume":"111","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Ravandi F, Riehl T, et al.: Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008, 111:1816\u20131819.","journal-title":"Blood"},{"key":"41_CR45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2006.05982.x","volume":"133","author":"DW Milligan","year":"2006","unstructured":"Milligan DW, Kochethu G, Dearden C, et al.: High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006, 133:173\u2013175.","journal-title":"Br J Haematol"},{"key":"41_CR46","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","volume":"106","author":"JG Gribben","year":"2005","unstructured":"Gribben JG, Zahrieh D, Stephans K, et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.","journal-title":"Blood"},{"key":"41_CR47","doi-asserted-by":"crossref","unstructured":"Hallek M, Fingerle-Rowson G, Fink AM, et al.: Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 325.","DOI":"10.1182\/blood.V112.11.325.325"},{"key":"41_CR48","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278\u20133281.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0041-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0041-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T16:05:10Z","timestamp":1590509110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0041-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0041-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}